NCT01424319 - Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Chronic Kidney DiseaseDiabetic Nephropathy

Interventions

DRUG

Atrasentan low dose group

Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.

DRUG

Atrasentan high dose group

Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.

DRUG

Atrasentan placebo group

Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.

Trial Locations (18)

Unknown

Site Reference ID/Investigator# 62022, Azumino

Site Reference ID/Investigator# 58124, Chiba

Site Reference ID/Investigator# 57486, Fujisawa

Site Reference ID/Investigator# 55097, Ibaraki

Site Reference ID/Investigator# 56982, Ina

Site Reference ID/Investigator# 55093, Kawagoe

Site Reference ID/Investigator# 57485, Kawasaki

Site Reference ID/Investigator# 55092, Kōriyama

Site Reference ID/Investigator# 56524, Matsumoto

Site Reference ID/Investigator# 57242, Nagano

Site Reference ID/Investigator# 55781, Nagoya

Site Reference ID/Investigator# 60965, Nagoya

Site Reference ID/Investigator# 55304, Suwa

Site Reference ID/Investigator# 59474, Tokyo

Site Reference ID/Investigator# 59967, Ueda

Site Reference ID/Investigator# 55095, Yokohama

Site Reference ID/Investigator# 57484, Yokohama

Site Reference ID/Investigator# 59842, Yokohama

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY